You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,202,079


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,202,079
Title:Bovine immunodeficiency virus (BIV) based vectors
Abstract: This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.
Inventor(s): Luo; Tianci (Clarksville, MD), Berkowitz; Robert David (San Francisco, CA), Kaleko; Michael (Rockville, MD)
Assignee: Novartis AG (Basel, CH)
Application Number:11/076,531
Patent Claims:1. A vector system comprising: a) a BIV vector construct comprising; i) a DNA segment from a BIV genome; ii) a packaging sequence necessary to package RNA into virions; iii) a promoter operably linked to the DNA segment; and iv) a transgene operably linked to a second promoter, wherein at least one of vpw, vpy and tat is deleted from said construct; b) a BIV packaging construct comprising: i) a BIV DNA sequence fragment comprising a gag gene, a pol gene or both of BIV; ii) a promoter operably linked to the BIV DNA sequence fragment; and iii) a polyadenylation sequence located downstream of the BIV DNA sequence fragment; and c) an expression construct comprising a gene encoding a viral surface protein.

2. The vector system of claim 1 wherein said expression construct is a vesicular stomatitis virus (VSV)-G envelope glycoprotein expression vector.

3. The vector system of claim 1 further comprising a BIV rev gene.

4. The vector system of claim 1, wherein said packaging sequence is a BIV packaging sequence.

5. The vector system of claim 1, wherein said transgene is operably linked to a mammalian promoter.

6. The vector system of claim 1 wherein said BIV vector construct further comprises a BIV rev-response element.

7. A cell line transfected with the vector system of claim 1, 2, 3, 4, 5, or 6.

8. The vector system of claim 1, wherein said packaging construct further comprises an RNA transport element.

9. The vector system of claim 8, wherein said transport element is a lentiviral rev responsive element (RRE).

10. The vector system of claim 9, wherein said RRE is a BIV RRE.

11. The vector system of claim 8, wherein said transport element is constitutive.

12. The vector system of claim 8, wherein said transport element is a Mason-Pfizer Monkey Virus element.

13. The vector system of claim 1, wherein said BIV DNA sequence fragment of said packaging vector further comprises an intron upstream of said gag gene, pol gene or both.

14. The vector system of claim 1, wherein said expression construct further comprises an operatively linked promoter.

15. The vector system of claim 1, wherein said expression construct further comprises an intron upstream of said gene encoding a viral surface protein.

16. The vector system of claim 1, wherein said transgene is operably linked to an internal promoter.

17. The vector system of claim 1, wherein any start codons in said packaging sequence are eliminated by deletion or mutation.

18. The vector system of claim 1, wherein said BIV vector construct further comprises a BIV cPPT.

19. The vector system of claim 1, wherein said BIV vector construct further comprises a 3' polypurine tract.

20. The vector system of claim 1, wherein said BIV vector comprises an RNA transport element.

21. The vector system of claim 20, wherein said transport element is a constitutive transport element.

22. A cell comprising the vector system of any one of claims 8 21.

23. A vector system comprising: a) a BIV vector construct comprising; a promoter linked to a first BIV R region; a BIV U5 element linked to said first BIV R region; a packaging sequence; a transgene; and a BIV U3 element linked to a second BIV R region, wherein said promoter initiates RNA transcription of the vector construct, and at least one of vpw, vpy and tat is deleted from said construct; b) a BIV packaging construct comprising: a BIV DNA sequence fragment comprising a gag gene, a pol gene or both of BIV; a promoter operably linked to said BIV DNA fragment; and a polyadenylation sequence located downstream of said BIV DNA fragment; and c) an expression construct comprising a gene encoding a viral surface protein.

24. The vector system of claim 23, wherein said transgene is operably linked to an internal promoter.

25. The vector system of claim 23, wherein said packaging sequence is a BIV packaging sequence.

26. The vector system of claim 23, wherein any start codons in said packaging sequence are eliminated by deletion or mutation.

27. The vector system of claim 23, wherein said BIV vector construct further comprises a BIV cPPT.

28. The vector system of claim 23, wherein said BIV vector construct further comprises a 3' polypurine tract.

29. The vector system of claim 23, wherein said BIV vector construct further comprises an RNA transport element.

30. The vector system of claim 29, wherein said RNA transport element is a BIV rev response element.

31. The vector system of claim 29, wherein said element is a constitutive transport element.

32. A cell comprising the vector system of any one of claims 23 31.

33. The vector system of claim 23, further comprising a BIV rev gene.

34. The vector system of claim 23, wherein said packaging construct further comprises an RNA transport element.

35. The vector system of claim 34, wherein said transport element is a lentiviral rev responsive element (RRE).

36. The vector system of claim 35, wherein said RRE is a BIV RRE.

37. The vector system of claim 34, wherein said transport element is constitutive.

38. The vector system of claim 34, wherein said transport element is a Mason-Pfizer Monkey Virus element.

39. The vector system of claim 23, wherein said BIV DNA sequence fragment of said packaging vector further comprises an intron upstream of said gag gene, pol gene or both.

40. The vector system of claim 23, wherein said expression construct further comprises an operatively linked promoter.

41. The vector system of claim 23, wherein said expression construct further comprises an intron upstream of said gene encoding a viral surface protein.

42. The vector system of claim 23, wherein said expression construct is a vesicular stomatitis virus (VSV)-G envelope glycoprotein expression vector.

43. The vector system of claim 23, wherein said transgene is operably linked to a mammalian promoter.

44. A cell line comprising the vector system of any one of claims 33 43.

Details for Patent 7,202,079

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2019-12-14
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2019-12-14
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2019-12-14
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.